Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo

Autor: Claudio Micheletto, F. Trevisan, R. W. Dal Negro, M Visconti, C. Pomari, Silvia Tognella
Rok vydání: 2004
Předmět:
Zdroj: Allergy. 59:289-294
ISSN: 1398-9995
0105-4538
DOI: 10.1046/j.1398-9995.2003.00351.x
Popis: Aspirin-induced asthma (AIA) is a clinical syndrome characterized by acute airway reaction to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDS). The most recent etiological hypothesises is that an overexpression of the enzyme LTC4 synthase occurs in AIA, with the consequent production of sulfidopeptide leukotrienes (LTs). Aim: Aim of the present study was to assess the effect of Montelukast, a selective cys-LT receptor antagonist, on nasal function, nasal reactivity to ASA and blood markers of eosinophilic inflammation in mild-to-moderate AIA. Material and methods: Thirty-six nonsmoker subjects with AIA (17 males, 22–52 years) performed a nasal provocation test (NPT) with lysine-aspirin (L-ASA) in baseline and after a 4-week Montelukast 10 mg or placebo treatment. Nasal function was assessed by the acoustic rhinomanometry, and they also performed a lung function test (forced expiratory volume in 1 s), and a blood sample for the eosinophil count and the eosinophil cationic protein (ECP) plasma measurements. After both treatments, all subjects repeated the NPT, the lung function, and the ECP and the eosinophil blood count. Statistical analysis: t-Test was used to compare mean values ± SD between groups, and P
Databáze: OpenAIRE